Birkenstock Holding (BIRK) 6-K 29 Feb 24 2023 Q1 Current report (foreign) Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Dec. 31, 2023
Document Information [Line Items]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Entity Registrant Name	Birkenstock Holding plc
Entity Central Index Key	0001977102
Current Fiscal Year End Date	--09-30
Entity File Number	001-41836

Condensed Consolidated Statemen

Condensed Consolidated Statements of Financial Position - EUR (€) € in Thousands	Dec. 31, 2023	Sep. 30, 2023
Non-current assets
Goodwill	€ 1,564,791	€ 1,593,917
Intangible assets (other than goodwill)	1,661,224	1,705,736
Property, plant and equipment	295,303	286,053
Right-of-use assets	148,245	122,984
Deferred tax assets	0	0
Other assets	52,045	38,234
Total non-current assets	3,721,608	3,746,924
Current assets
Inventories	644,367	595,092
Right to return assets	1,138	1,132
Trade and other receivables	79,497	91,764
Current tax assets	10,108	10,361
Other current assets	36,849	37,789
Cash and cash equivalents	169,379	344,408
Total current assets	941,338	1,080,546
Total assets	4,662,946	4,827,470
Shareholders' equity
Ordinary shares	0	182,721
Share premium	2,524,231	1,894,384
Treasury shares	(343,645)
Other capital reserve	68,985	65,394
Retained earnings	218,822	225,976
Accumulated other comprehensive income	(6,464)	32,113
Total shareholders' equity	2,461,930	2,400,589
Non-current liabilities
Loans and borrowings	1,292,785	1,815,695
Tax receivable agreement liability	333,204
Lease liabilities	124,319	103,049
Provisions for employee benefits	2,745	2,716
Other provisions	1,807	2,074
Deferred tax liabilities	109,543	109,794
Deferred income	13,299	10,634
Other liabilities	4,688	4,338
Total non-current liabilities	1,882,389	2,048,300
Current liabilities
Loans and borrowings	23,408	37,343
Lease liabilities	31,781	27,010
Trade and other payables	104,219	123,012
Accrued liabilities	23,057	38,645
Other financial liabilities	913	7,085
Other provisions	24,574	36,495
Contract liabilities	14,995	7,018
Current tax liabilities	83,659	83,332
Deferred income	0	2,680
Other current liabilities	12,021	15,961
Total current liabilities	318,626	378,581
Total liabilities	2,201,015	2,426,881
Total shareholders' equity and liabilities	€ 4,662,946	€ 4,827,470

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - EUR (€) € in Thousands	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Line Items]
Revenue	€ 302,924	€ 248,490
Cost of sales	(118,056)	(95,170)
Gross profit	184,868	153,320
Operating expenses
Selling and distribution expenses	(103,484)	(86,119)
General administrative expenses	(34,391)	(22,133)
Foreign exchange gain (loss)	(11,655)	(30,830)
Other income (expense), net	231
Profit from operations	35,570	14,238
Finance cost, net	(36,050)	(25,098)
Profit (loss) before tax	(480)	(10,861)
Income tax benefit (expense)	(6,674)	1,674
Net profit (loss)	(7,154)	(9,187)
Items that may be reclassified to profit (loss) in subsequent periods (net of tax):
Cumulative translation adjustment gain (loss)	(37,616)	(81,704)
Net position of fair value changes of the cash flow hedge	(961)
Items that will not be reclassified to profit in subsequent periods:
Other comprehensive income (loss)	(38,577)	(81,704)
Total comprehensive income (loss)	€ (45,731)	€ (90,891)
Earnings (loss) per share
Basic	€ (0.04)	€ (0.05)
Diluted	€ (0.04)	€ (0.05)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) (Unaudited) - EUR (€) € in Thousands	Total	Ordinary Shares	Share Premium	Treasury Shares	Other Capital Reserve	Retained Earnings (Accumulated Deficit)	Cumulative translation adjustment	Cash flow hedge reserve
Equity at beginning of period at Sep. 30, 2022	€ 2,357,818	€ 182,721	€ 1,894,384			€ 150,954	€ 129,759
Number of units or Shares outstanding at Sep. 30, 2022		182,721,369
Net profit (loss)	(9,187)					(9,187)
Other comprehensive income (loss)	(81,704)						(81,704)
Total comprehensive income (loss)	(90,891)					(9,187)	(81,704)
Equity at end of period at Dec. 31, 2022	2,266,928	€ 182,721	1,894,384			141,768	48,055
Number of units or Shares outstanding at Dec. 31, 2022		182,721,369
Equity at beginning of period at Sep. 30, 2023	2,400,589	€ 182,721	1,894,384		€ 65,394	225,976	32,458	€ (345)
Number of units or Shares outstanding at Sep. 30, 2023		182,721,369
Net profit (loss)	(7,154)					(7,154)
Other comprehensive income (loss)	(38,577)						(37,616)	(961)
Total comprehensive income (loss)	(45,731)					(7,154)	(37,616)	(961)
Equity-settled share-based compensation expense	3,591				3,591
Conversion to no par value ordinary shares		€ (182,721)	182,721
Shares re-purchased in consideration of TRA	(343,645)			€ (343,645)
Shares re-purchased in consideration of TRA, shares		(5,648,465)
Issuance of share capital, net (of transaction costs)	447,126		447,126
Issuance of share capital, net (of transaction costs), shares		10,752,688
Equity at end of period at Dec. 31, 2023	€ 2,461,930		€ 2,524,231	€ (343,645)	€ 68,985	€ 218,822	€ (5,158)	€ (1,306)
Number of units or Shares outstanding at Dec. 31, 2023		187,825,592

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Shareholders' Equity (Deficit) (Unaudited) (Parenthetical) € in Millions	3 Months Ended
	Dec. 31, 2023 EUR (€)
Statement of changes in equity [abstract]
Issuance of share capital net of transaction costs	€ 22.7

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - EUR (€) € in Thousands	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Cash flows from operating activities
Net profit (loss)	€ (7,154)	€ (9,187)
Adjustments to reconcile net profit (loss) to net cash flows from operating activities:
Depreciation	16,171	13,097
Amortization	7,076	7,320
Finance cost, net	36,050	25,098
Net exchange differences	11,720	30,804
Non-cash operating items	2,389	910
Income tax expense	6,674	(1,674)
Income tax paid	(3,841)	(3,118)
MIP personal income tax paid	(11,426)
Changes in working capital
Inventories	(66,937)	(64,437)
Trade and other receivables	10,982	4,582
Trade and other payables	(15,937)	(38,530)
Accrued Liabilities	(15,195)	(4,529)
Other current financial liabilities	(6,172)	(20,285)
Other current provision	(11,693)	(4,876)
Contract liabilities	8,223	2,039
Prepayments	(9,919)	8
Other	3,565	9,606
Net cash flows (used in) operating activities	(45,426)	(53,172)
Cash flows from investing activities
Interest received	1,216
Purchase of property, plant and equipment	(18,111)	(25,711)
Purchase of intangible assets	(488)	(209)
Receipt of government grant	8,739
Net cash flows (used in) investing activities	(8,644)	(25,920)
Cash flows from financing activities
IPO Proceeds, net of transaction costs	449,297
Repayments of loans and borrowings	(524,514)	(1,995)
Interest paid	(34,423)	(38,972)
Payments of lease liabilities	(8,266)	(6,931)
Interest portion of lease liabilities	(1,845)	(1,340)
Net cash flows (used in) financing activities	(119,752)	(49,240)
Net increase (decrease) in cash and cash equivalents	(173,822)	(128,331)
Cash and cash equivalents at beginning of period	344,408	307,078
Net foreign exchange difference	(1,207)	(7,686)
Cash and cash equivalents at end of period	€ 169,379	€ 171,060

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) € in Millions	3 Months Ended
	Dec. 31, 2023 EUR (€)
Statement of cash flows [abstract]
IPO proceeds underwriting commission fees	€ 19.8

General Information

General Information	3 Months Ended
	Dec. 31, 2023
General Information [Abstract]
General Information	1. GENERAL INFORMATION Organization and principal activities Birkenstock Holding plc (formerly: Birkenstock Holding Limited) (together with its subsidiaries referred to herein as the “Company”, “Birkenstock” or the “Group”) was formed under the name of BK LC Lux Finco 2 S. à r.l. on February 19, 2021, as a limited liability company organized under Luxembourg law, with its business address at 40 Avenue Monterey, Luxembourg. On October 4, 2023, the Company converted to a public limited company organized under Jersey law and changed its name to Birkenstock Holding plc. The Company’s current business address is 1-2 Berkeley Square, London W1J 6EA, United Kingdom. The Company is registered at the Jersey Financial Services Commission under number 148522. The Company’s controlling shareholder is BK LC Lux MidCo S. à r.l. (“MidCo”) and the Company’s ultimate controlling shareholder is LC9 Caledonia AIV GP, LLP (“ L Catterton”). The Company manufactures and sells footbed-based products, including sandals and closed-toe silhouettes, and other products, such as skincare and accessories, for everyday leisure, and work. The Company operates in four operating segments based on its regional hubs: (1) Americas, (2) Europe, (3) Asia, the South Pacific, and Australia (“ASPA”), and (4) the Middle East, Africa, and India (“MEAI”) (see Note 5 – Segment information for further details). All segments have the same operations. The Company sells its products through two main channels: business-to-business (“B2B”) (comprising sales made to established third-party store networks), and direct-to-consumer (“DTC”) (comprising sales made on globally owned online stores via the Birkenstock.com domain and sales made in Birkenstock retail stores). Seasonality Revenue of our products are affected by a seasonal pattern that is driven in large part by the weather given the nature of our product mix. The seasonal nature of our business is similar across geographies and sales channels with B2B seeing an increase in revenue in the spring months, while revenue in the DTC channel increasing in the summer. Between October and March, we manufacture our products for the B2B channel, and during the first few months of the calendar year, we rely on our built-up inventory for our revenue to B2B partners. Starting in April and during the warmer months of the year, demand for our products from the DTC channel increases. While these consumer buying patterns lead to a natural seasonality in revenue, unseasonable weather could significantly affect revenue and profitability. Our geographical breadth, customer diversity and our strategic focus on expanding certain product categories and entering new territory helps to mitigate part of the effect of seasonality on results of operations.

Basis of Presentation

Basis of Presentation	3 Months Ended
	Dec. 31, 2023
Basis of Presentation [Abstract]
Basis of Presentation	2. BASIS OF PRESENTATION Basis of preparation and consolidation These interim condensed consolidated financial statements were authorized for issuance by the Company’s Audit Committee on February 29, 2024. These interim condensed consolidated financial statements as of December 31, 2023 and September 30, 2023 and for the three months ended December 31, 2023 and December 31, 2022 have been prepared in accordance with International Accounting Standard ("IAS") 34 "Interim Financial Reporting", as issued by the International Accounting Standard Board (“IASB”). These interim condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements for the fiscal year ended September 30, 2023, which have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the IASB, taking into account the recommendations of the International Financial Reporting Standards Interpretations Committee (“IFRIC”). These interim condensed consolidated financial statements have been prepared on a historical cost basis except for derivative financial instruments and the initial recognition of assets acquired and liabilities assumed in a business combination which are recorded at fair value. The interim condensed consolidated financial statements comprise the financial statements of Birkenstock Holding plc and its subsidiaries. All intercompany transactions and balances have been eliminated. All amounts have been rounded to the nearest thousand, unless otherwise indicated. The fiscal year of the Company ends on September 30. The companies consolidated in these interim condensed consolidated financial statements are disclosed in the notes to the annual consolidated financial statements for the fiscal year ended September 30, 2023. Functional and presentation currency The functional currency of each of the Company’s subsidiaries is the currency of the primary economic environment in which each entity operates. The presentation currency of the Company is Euros.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Dec. 31, 2023
Significant Accounting Policies [Abstract]
Significant Accounting Policies	3. SIGNIFICANT ACCOUNTING POLICIES The accounting policies applied in these interim condensed consolidated financial statements are predominantly the same as those applied by Birkenstock in its consolidated financial statements for the fiscal year ended September 30, 2023. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective. Change in accounting estimate The Company distributes its footwear produced predominantly in Germany and Portugal to its own (distribution) legal entities around the world with an intercompany margin, which is being eliminated at consolidated level. The intercompany profit elimination ("ICP") has been calculated and applied on a consistent manner up through September 30, 2023. However, it is based on various, high-level assumptions. This ICP model has been replaced with a more detailed method reflecting the precise inventory turnover rate per product style, i.e., Boston, Arizona, and color. This more accurate computation also has a foreign currency impact on the Cost of Sales converted to the reporting currency Euro. If the prior ICP model computation had been applied still in this fiscal year, the Company would have recorded an incremental expense (Cost of Sales) of € 13.5 for both aspects (ICP and FX) in the three months ended December 31, 2023. Deferred offering costs The Company capitalizes certain legal, professional accounting, and other third-party fees that are directly associated with the issuance of shares as deferred offering costs and recorded these in line item other financial assets until such equity financing is consummated. After consummation, these deferred costs are recorded within equity as a reduction to the share premium generated as a result of the offering. The Company closed its initial public offering during the three months ended December 31, 2023, and therefore a total of € 2.9 million deferred offering costs were recorded as a reduction of share premium. No deferred offering costs were capitalized as of December 31, 2023 . New and amended standards and interpretations adopted by the Company The following amended standards became effective for the Company’s fiscal year beginning on October 1, 2023, but did not have a material impact on the unaudited interim condensed consolidated financial statements of the Company: • IFRS 17 - Insurance Contracts (effective for annual periods beginning on or after January 1, 2023). • Amendments to IFRS 17 – Insurance Contracts (effective for annual periods beginning on or after January 1, 2023). • IFRS 17 and IFRS 9 – Initial application of IFRS 17 and IFRS 9 – Comparative Information (effective for annual periods beginning on or after January 1, 2023). • Amendments to IAS 8 – Definition of Accounting Estimates (effective for annual periods beginning on or after January 1, 2023). • Amendments to IAS 1 and IFRS Practice Statement 2 - Disclosure of Accounting Policies (effective for annual periods beginning on or after January 1, 2023). • Amendments to IAS 12 – Deferred Tax related to Assets and Liabilities arising from a Single Transaction (effective for annual periods beginning on or after January 1, 2023). • Amendments to IAS 12 – International Tax Reform - Pillar 2 Model Rules (effective for annual periods beginning on or after January 1, 2023, however a temporary exception from accounting for deferred taxes arising from the implementation of the OECD’s Pillar Two model rules is to be applied retroactively). The mandatory temporary exemption to account for deferred taxes has been applied. New and amended standards and interpretations issued but not yet effective The following standard amendments will be effective beginning October 1, 2024 and are not expected to have a material impact on the unaudited interim condensed consolidated financial statements of the Company: • Amendments to IAS 1 – Non-current liabilities with Covenants (effective for annual periods beginning on or after January 1, 2024). • Amendments to IAS 1 – Classification of Liabilities as current or non-current (effective for annual periods beginning on or after January 1, 2024). • Amendments to IFRS 16 – Lease liability in a sale and lease back (effective for annual periods beginning on or after January 1, 2024). • Amendments to IAS 7 and IFRS 7 – Supplier Finance Arrangements (effective for annual periods beginning on or after January 1, 2024). • Amendments to IAS 21 – Lack of Exchangeability (effective for annual periods beginning on or after January 1, 2025). • Amendments to IFRS 10 and IAS 28 – Sale or contribution of assets between an investor and its associate or joint venture (available for optional adoption/ effective date deferred indefinitely).

Significant Accounting Estimate

Significant Accounting Estimates, Assumptions and Judgments	3 Months Ended
	Dec. 31, 2023
Significant Accounting Estimates, Assumptions and Judgments [abstract]
Significant Accounting Estimates, Assumptions and Judgments	4. SIGNIFICANT ACCOUNTING ESTIMATES, ASSUMPTIONS AND JUDGMENTS The preparation of Birkenstock’s consolidated financial statements in accordance with IFRS requires management to make estimates and judgments in applying the Company’s accounting policies that affect the reported amounts and disclosures made in the interim condensed consolidated financial statements and accompanying notes. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods. The estimates and underlying assumptions are subject to continuous review. During the three months ended December 31, 2023, the Company made significant estimates and assumptions to determine the Company's contractual obligations and its fair value under the Tax Receivable Agreement entered into, between the Company and MidCo, on October 10, 2023 (the "Tax Receivable Agreement" or "TRA"). These significant estimates and assumptions include forecasting taxable income and estimating the timing of when certain taxable benefits will be realized in future years. For details on the TRA please refer to Note 12 - Tax Receivable Agreement . In preparing the interim condensed consolidated financial statements, no significant changes in accounting estimates, assumptions and judgments have occurred compared to the significant accounting judgments, estimates and assumptions discussed in the consolidated financial statements as of and for the fiscal year ended September 30, 2023, except for the change in estimate described above.

Segment Information

Segment Information	3 Months Ended
	Dec. 31, 2023
Disclosure of operating segments [abstract]
Segment Information	5. SEGMENT INFORMATION The Company’s operating segments are reported in a manner consistent with the internal reporting provided to and regularly reviewed by the chief operating decision maker (“CODM”), the Chief Executive Officer (“CEO”), and are aligned to the four geographical hubs that the Company operates in: Americas, Europe, ASPA, and MEAI. Due to the materiality, ASPA and MEAI are aggregated into one reportable segment APMA (“Asia Pacific, Middle East, Africa”). As such the Company has three reportable segments – Americas, Europe and APMA. Additionally, the Company has a Corporate / Other revenue and expenses, which primarily consists of non-core activities from the cosmetics and sleeping systems businesses, as well as other administrative costs that are not charged to the operating segments and realized foreign exchange gains and losses. The CODM uses the measure of adjusted EBITDA to assess operating segments’ performance to make decisions regarding the allocation of resources. The adjustments to EBITDA relate to realized and unrealized foreign exchange gain / (loss), initial public offering ("IPO")-related costs, share-based compensation and other adjustments relating to non-recurring items. As of March 31, 2023, the Company changed its internal reporting to the CODM to report results prepared in accordance with IFRS. Comparative segment results have been retrospectively adjusted accordingly. Assets and liabilities are neither reported nor reviewed by the CODM at the operating segment level. Three months ended December 31, 2023 (In thousands of Euros) Americas Europe APMA Total Reportable Segments Corporate / Other Total Revenue 181,453 80,134 39,478 301,065 1,859 302,924 Adjusted EBITDA 51,553 23,137 12,184 86,874 ( 5,518 ) 81,356 IPO-related costs ( 7,294 ) Realized and unrealized FX gains / losses ( 11,655 ) Share-based compensation expenses ( 3,591 ) EBITDA 58,817 Depreciation and amortization ( 23,247 ) Finance cost, net ( 36,050 ) Profit before tax ( 480 ) Three months ended December 31, 2022 (In thousands of Euros) Americas Europe APMA Total Reportable Segments Corporate / Other Total Revenue 159,799 60,517 26,913 247,229 1,261 248,490 Adjusted EBITDA 54,632 13,492 6,088 74,212 ( 1,817 ) 72,395 IPO-related costs ( 5,343 ) Realized and unrealized FX gains / losses ( 30,830 ) Other ( 1,569 ) EBITDA 34,654 Depreciation and amortization ( 20,417 ) Finance cost, net ( 25,098 ) Profit before tax ( 10,861 )

Financial Risk Management Objec

Financial Risk Management Objectives and Policies	3 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about financial instruments [abstract]
Financial Instruments and Financial Risk Management	10. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT The following table presents the fair values and fair value hierarchy of the Company’s financial instruments that are carried at fair value on a recurring basis in the consolidated statements of financial position: Fair value (In thousands of Euros) Level Measurement December 31, September 30, Derivative assets 36,727 31,708 Derivative assets not designated as hedging instruments 2 FVtPL 35,629 28,795 Derivative assets designated as hedging instruments 2 FVtOCI 1,098 2,913 Derivative liabilities 2 FVtPL 480 6,925 Changes in fair value of derivative assets and liabilities are recognized within the consolidated statements of profit or loss except for changes in the fair value of derivative financial instruments designated as hedging instruments which are recognized within other comprehensive income. The Company does not carry any further financial instruments at fair value either on a recurring or non-recurring basis. The derivative assets and liabilities are reflected in the statements of financial position within other assets, other current assets and other financial liabilities. The following table presents the fair value and fair value hierarchy of the Company’s loans and borrowings carried at amortized cost: (In thousands of Euros) Level Nominal value Carrying value Fair value December 31, 2023 Term Loan (EUR) 2 375,000 369,388 384,315 Term Loan (USD) 2 299,083 296,974 312,364 Vendor Loan 2 199,560 207,437 189,090 Senior Notes 2 428,500 442,393 414,149 September 30, 2023 Term Loan (EUR) 2 375,000 368,701 348,426 Term Loan (USD) 2 781,315 730,855 694,889 Vendor Loan 2 299,560 305,048 235,687 Senior Notes 2 428,500 448,434 373,682 There were no transfers between levels during any reporting period. There were no changes in the Group’s valuation processes, valuation techniques and types of inputs used in the fair value measurements during the reporting period. Financial risk management Birkenstock has exposure to credit risk, liquidity risk and market risk. The interim condensed consolidated financial statements do not include all financial risk information and disclosures required in the annual financial statements and should be read in conjunction with Birkenstock’s annual financial statements for the fiscal years ended September 30, 2023. Capital management The Board of Directors of the Company monitors the Company’s capital management on a regular basis. The Company continually assesses the adequacy of the Company’s capital structure and capacity and adjusts within the context of the Company’s strategy, economic conditions, and risk characteristics of the business.

Property, Plant and Equipment

Property, Plant and Equipment	3 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about property, plant and equipment [abstract]
Property, Plant and Equipment	6. PROPERTY, PLA NT AND EQUIPMENT During the three months ended December 31, 2023 and 2022, the Company acquired property, plant and equipment with costs of € 16.4 million and € 25.7 million, respectively. The additions in the three months ended December 31, 2023 and 2022, are mainly related to investments in a production facility in Pasewalk, Germany, and a production facility in Arouca, Portugal.

Right-of-Use Assets

Right-of-Use Assets	3 Months Ended
	Dec. 31, 2023
Presentation of leases for lessee [abstract]
Right-of-Use Assets	7. RIGHT-OF-USE ASSETS The right-of-use assets amount to € 148.2 million as of December 31, 2023 and € 123.0 million as of September 30, 2023. The increase during the three months ended December 31, 2023 is mainly related to a new lease agreement for a warehouse in the United States and three new stores.

Inventories

Inventories	3 Months Ended
	Dec. 31, 2023
Disclosure Of Inventories [Abstract]
Inventories	8. INVENTORIES (In thousands of Euros) December 31, September 30, Raw materials 81,567 69,580 Work in progress 29,166 23,102 Finished goods 533,634 502,410 Total inventories at the lower of cost and net realizable value 644,367 595,092 During the three months ended December 31, 2023 and 2022, inventories of € 54.9 million and € 41.6 m illion, respectively, were recognized as an expense and included in cost of sales. Write-downs of inventories during the three months ended December 31, 2023 were € 2.7 million. No write-downs were recognized during the three months ended December 31, 2022.

Equity

Equity	3 Months Ended
	Dec. 31, 2023
Equity [abstract]
Equity	9. EQUITY Initial Public Offering On October 13, 2023, the Company closed its IPO. Birkenstock issued and sold 10,752,688 ordinary shares at an initial public offering price of $ 46.00 . The total proceeds from the IPO available to Birkenstock, net of underwriting discounts and commissions but before expenses, amounted to $ 473.6 million. The underwriting commission fees for the IPO totaled € 19.8 million. The deferred offering costs, which were deducted from Share Premium as part of the IPO transaction, amounted to € 2.9 million. The Company used the majority of the proceeds received from the IPO, together with cash on hand, to repay € 100.0 million in aggregate principal amount of the loan outstanding under the agreement with AB-Beteiligungs GmbH (the "Vendor Loan") and $ 450.0 million in aggregate principal amount of borrowings outstanding under the United States dollar (USD) denominated facility included within a senior facilities agreement entered into by our subsidiary Birkenstock Limited Partner S.à r.l. in April 2021 (the "USD TLB Facility"). Capital Reorganization Prior to the IPO, the Company performed a capital reorganization. On October 2, 2023, the Company converted its share capital, comprised of 182,721,369 ordinary shares of € 1.00 each into 182,721,369 no par value ordinary shares. In addition, on October 10, 2023, the Company entered into the TRA with MidCo in consideration for the repurchase of 5,648,465 ordinary shares of the Company from MidCo. Please refer to Note 12 – Tax Receivable Agreement for further details on the TRA. As of October 13, 2023 and December 31, 2023, the Company had 187,825,592 no par value ordinary shares outstanding.

Financial Instruments and Finan

Financial Instruments and Financial Risk Management	3 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about financial instruments [abstract]
Financial Instruments and Financial Risk Management	10. FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT The following table presents the fair values and fair value hierarchy of the Company’s financial instruments that are carried at fair value on a recurring basis in the consolidated statements of financial position: Fair value (In thousands of Euros) Level Measurement December 31, September 30, Derivative assets 36,727 31,708 Derivative assets not designated as hedging instruments 2 FVtPL 35,629 28,795 Derivative assets designated as hedging instruments 2 FVtOCI 1,098 2,913 Derivative liabilities 2 FVtPL 480 6,925 Changes in fair value of derivative assets and liabilities are recognized within the consolidated statements of profit or loss except for changes in the fair value of derivative financial instruments designated as hedging instruments which are recognized within other comprehensive income. The Company does not carry any further financial instruments at fair value either on a recurring or non-recurring basis. The derivative assets and liabilities are reflected in the statements of financial position within other assets, other current assets and other financial liabilities. The following table presents the fair value and fair value hierarchy of the Company’s loans and borrowings carried at amortized cost: (In thousands of Euros) Level Nominal value Carrying value Fair value December 31, 2023 Term Loan (EUR) 2 375,000 369,388 384,315 Term Loan (USD) 2 299,083 296,974 312,364 Vendor Loan 2 199,560 207,437 189,090 Senior Notes 2 428,500 442,393 414,149 September 30, 2023 Term Loan (EUR) 2 375,000 368,701 348,426 Term Loan (USD) 2 781,315 730,855 694,889 Vendor Loan 2 299,560 305,048 235,687 Senior Notes 2 428,500 448,434 373,682 There were no transfers between levels during any reporting period. There were no changes in the Group’s valuation processes, valuation techniques and types of inputs used in the fair value measurements during the reporting period. Financial risk management Birkenstock has exposure to credit risk, liquidity risk and market risk. The interim condensed consolidated financial statements do not include all financial risk information and disclosures required in the annual financial statements and should be read in conjunction with Birkenstock’s annual financial statements for the fiscal years ended September 30, 2023. Capital management The Board of Directors of the Company monitors the Company’s capital management on a regular basis. The Company continually assesses the adequacy of the Company’s capital structure and capacity and adjusts within the context of the Company’s strategy, economic conditions, and risk characteristics of the business.

Loans and Borrowings

Loans and Borrowings	3 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about borrowings [abstract]
Loans and Borrowings	11. LOANS AND BORROWINGS The Company has the following principal and interest payable amounts outstanding for loans and borrowings: (In thousands of Euros) Currency Year of maturity December 31, September 30, Non-current liabilities Term Loan (EUR) EUR 2028 375,000 375,000 Term Loan (USD) USD 2028 296,103 730,159 Vendor Loan EUR 2029 199,560 299,560 Senior Notes EUR 2029 428,500 428,500 1,299,163 1,833,220 Senior Note embedded derivative 28,638 28,638 Less: amortization under the effective interest method ( 35,016 ) ( 46,163 ) 1,292,785 1,815,695 Current liabilities Term Loan (EUR) interest payable EUR N/A 4,358 4,197 Term Loan (USD) - current portion USD 2028 2,980 7,347 Term Loan (USD) interest payable USD N/A 4,444 10,938 Vendor Loan interest payable EUR N/A 7,877 5,487 Senior Notes interest payable EUR N/A 3,749 9,373 23,408 37,343 During the three months ended December 31, 2023, the Company made early repayments of € 100.0 million of the Vendor Loan and $ 450.0 million of the USD Term Loan Facility.

Tax Receivable Agreement

Tax Receivable Agreement	3 Months Ended
	Dec. 31, 2023
Tax Receivable Agreement [Abstract]
Tax Receivable Agreement	12. TAX RECEIVABLE AGREEMENT On October 10, 2023, the Company entered into the Tax Receivable Agreement with MidCo (together with its permitted successors and assignees' shareholders, the "TRA Participants"). Pursuant to the TRA, the Company must make certain tax benefit payments (which are to be paid in cash in USD) to MidCo as consideration for the Company’s repurchase of 5,648,465 of its ordinary shares from MidCo. (please refer to Note 9 - Equity ). The TRA requires the Company to make payments to the TRA Participants equal to 85 % of certain tax savings (or expected tax savings) in respect of the certain tax benefits, over the next approximately 13 years , that were created by MidCo’s acquisition of the Company in 2021 or that were otherwise available to the Company as of the date of the IPO. Under the TRA, generally, the Company will retain the benefit of the remaining 15 % of the applicable tax savings. The timing of payments under the TRA will vary depending upon a number of factors, including the amount, character and timing of the Company's taxable income in the future. The future payments expected to be made under the TRA may total approximately $ 554.7 million in aggregate over the next 13 years (equaling the total undiscounted TRA payment amount) . The fair value (level 3 Fair Value assessment) of these future payments was determined to be € 343.6 million as of October 10, 2023. At inception the fair value was calculated based on cash flows with an assumption regarding expected tax payments as well as a discounting to a present value. As the TRA can be terminated by the Company or the TRA participants, the fair value was determined under the assumption that such early payment could be demanded. The fair value together with the expected cash flows determine the original effective interest rate. In general, payments under the TRA are expected to be made only in periods following the filing of a tax return in which the Company is able to utilize certain tax benefits to reduce cash taxes paid to a taxing authority. The impact of any changes in the projected obligations under the TRA as a result of changes in the future taxable income, changes in tax legislation or tax rates, or other factors that may impact the Company’s tax savings will be reflected in other income/ expense, net, in the condensed consolidated statements of comprehensive income in the period in which the change occurs. During the three months ended December 31, 2023 there were no material changes in the fair value or the contractual obligation. Subsequently to its inception, the TRA is measured at amortized cost taking into consideration the current expected cash flows and the original effective interest rate. The liability is discounted via the effective-interest-method and the expenses are recognized within interest expenses. As payments under the TRA are to be made in USD, the TRA liability is remeasured to the Company's reporting currency at each reporting period, with foreign exchange gains or losses recognized in the statement of comprehensive income (loss). The ending balance of the TRA liability as of December 31, 2023 amounted to € 333.2 million. Considering the filing deadlines for the tax returns and the approval and payment procedures under the TRA, this is a non-current financial liability for December 31, 2023 with the first pay-out to be expected in the second half of fiscal 2025.

Deferred Income

Deferred Income	3 Months Ended
	Dec. 31, 2023
Deferred income [abstract]
Deferred Income	13. DEFERRED INCOME (In thousands of Euros) Government Grants Other Balance at September 30, 2023 10,634 2,680 Pledged during the year 84 — Received during the year — 140 Released to the statement of comprehensive income ( 125 ) — Impact of foreign currency translation — ( 114 ) Balance at December 31, 2023 10,593 2,706 current — — non-current 10,593 2,706 In the fiscal year ended September 30, 2023 the Group was awarded a government grant by the State of Mecklenburg-Vorpommern, amounting up to € 11.3 million, conditional on the investment in a production facility and the creation of 400 permanent jobs in Pasewalk, Germany. The grant is recognized as deferred income and is released to the statement of comprehensive income over the useful life of the respective assets. € 8.7 million of cash from the State Mecklenburg-Vorpommern were received on November 23, 2023 and recorded as a reduction of the other financial assets.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	3 Months Ended
	Dec. 31, 2023
Revenue [abstract]
Revenue from Contracts with Customers	14. REVENUE FROM CONTRACTS WITH CUSTOMERS For disaggregation of revenue by geography refer to Note 5 – Segment information . Disaggregation of revenue by sales channels was as follows: Three months ended December 31, (In thousands of Euros) 2023 2022 B2B 140,410 117,794 DTC 160,655 129,435 Other 1,859 1,261 Total revenue 302,924 248,490 Our B2B and DTC channels generate revenue across each of our reportable segments, with B2B revenue being more prominent in each segment. In our Americas and Europe reportable segments, the distribution between B2B and DTC revenue approximates the distribution for the consolidated group. In our APMA reportable segment, the proportion of B2B revenue is greater than the distribution for the consolidated group.

Operating Expenses

Operating Expenses	3 Months Ended
	Dec. 31, 2023
Notes and other explanatory information [abstract]
Operating Expenses	OPERATING EXPENSES Cost of sales Three months ended December 31, (In thousands of Euros) 2023 2022 Depreciation & amortization ( 4,397 ) ( 3,413 ) Personnel costs ( 40,388 ) ( 33,461 ) Cost of materials ( 54,877 ) ( 41,568 ) Properties & buildings maintenance, occupancy and incidental costs ( 6,613 ) ( 4,270 ) Logistic expenses ( 1,289 ) ( 1,007 ) IT & Consulting ( 8,221 ) ( 6,401 ) Other ( 2,271 ) ( 5,052 ) Cost of sales ( 118,056 ) ( 95,170 ) Selling and distribution expenses Three months ended December 31, (In thousands of Euros) 2023 2022 Depreciation & amortization ( 14,681 ) ( 14,305 ) Personnel costs ( 21,105 ) ( 18,019 ) Marketing and selling expenses ( 29,042 ) ( 23,572 ) Logistic expenses ( 29,764 ) ( 13,358 ) IT & Consulting ( 8,204 ) ( 12,429 ) Other ( 687 ) ( 4,436 ) Selling and distribution expenses ( 103,484 ) ( 86,119 ) General administration expenses Three months ended December 31, (In thousands of Euros) 2023 2022 Depreciation & amortization ( 4,169 ) ( 2,699 ) Personnel costs ( 16,837 ) ( 12,466 ) Insurance ( 1,538 ) ( 627 ) IT & Consulting ( 73 ) ( 4,535 ) Other ( 11,773 ) ( 1,805 ) General administration expenses ( 34,391 ) ( 22,133 )

Income Tax

Income Tax	3 Months Ended
	Dec. 31, 2023
Disclosure of income tax [abstract]
Income Tax	16. INCOME TAX The Group determined the reporting periods’ income tax expense based on an estimate of the annual effective income tax rate in the respective countries applied to the pre-tax result before the tax effect of any discrete items of this reporting period. The major components of income tax expenses are as follows: Three months ended December 31, (In thousands of Euros) 2023 2022 Current income taxes ( 4,610 ) ( 4,648 ) Deferred income taxes ( 2,064 ) 6,322 Income tax expense ( 6,674 ) 1,674 The Group estimates the income tax rate for the year ending September 30, 2024 will be 34.4 % (and it was 34.6 % for the year ended September 30, 2023). The effective tax rate for the period ended December 31, 2023, was impacted by personnel expenses resulting from the management investment plan described in Note 18 – Share-based compensation that are treated as non-deductible for income tax purposes. For details on the TRA please refer to Note 12 - Tax Receivable Agreement (TRA) .

Earnings Per Share

Earnings Per Share	3 Months Ended
	Dec. 31, 2023
Earnings per share [abstract]
Earnings Per Share	17. EARNI NGS PER SHARE Basic and diluted earnings per share is calculated by dividing net profit (loss) attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the reporting period. For comparison purposes, the earnings per share calculation for the three months ended December 31, 2022, was adjusted to the weighted average number of ordinary shares outstanding as of December 31, 2023. The calculation of earnings per share is as follows: Three months ended December 31, (In thousands of Euros, except share and per share information) 2023 2022 Weighted number of outstanding shares 186,920,154 182,721,369 Number of shares with dilutive effects — — Weighted number of outstanding shares (diluted and undiluted) 186,920,154 182,721,369 Net profit (loss) attributable to ordinary shareholders ( 7,154 ) ( 9,187 ) Basic ( 0.04 ) ( 0.05 ) Diluted ( 0.04 ) ( 0.05 ) The Company's management investment plan has no dilutive effect on the earnings per share calculation as all granted awards will be settled by an immediate parent rather than by the Company itself. For further information please refer to Note 18 – Share-based compensation.

Share-based Compensation

Share-based Compensation	3 Months Ended
	Dec. 31, 2023
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Share-based Compensation	18. SHARE-BASED COMPENSATION Selected senior executives of Birkenstock management were given an opportunity to participate in the management investment plan ("MIP") of MidCo and to indirectly invest in MidCo by purchasing a partial limited partnership interest in, and becoming a limited partner of, BK LC Manco GmbH & Co. KG, a German limited partnership, which holds certain ordinary shares in MidCo, a Luxembourg limited liability company, which is the immediate parent of Birkenstock. In March 2023, awards for 1,197,100 shares of BK LC Manco GmbH & Co. KG were granted in five separate tranches each representing 20 % of the shares. No ne of these awards has been forfeited/ canceled/ settled as of the reporting date. The MIP is accounted for as equity-settled share-based payment transaction in scope of IFRS 2. The vesting periods are up to four years , with 20 % of the awards vesting after each year of service provided. The last 20 % vests only with an occurrence of an exit. As of the grant date, the Company deemed it more likely than not that an exit event would occur more than 12 months after the grant. Therefore, for the first 20 % tranche, the occurrence of an exit event was accounted for as a market condition and was included in the grant date fair value of the awards. For the remaining tranches, the occurrence of an exit event was accounted for as a non-market vesting condition. The Company has considered several scenarios for the timing of the exit event and assigned appropriate probabilities to them. The weighted average fair value of the awards granted under the MIP was € 57.57 . The fair value at grant date was estimated using a Discounted Cash Flow model and then a Black-Scholes option pricing model, weighted for the assigned probability of each exit event date scenario. The model takes into account, among other things, a self-investment as well as the potential development of Birkenstock's ordinary redeemable share price. The historical volatility was derived from a peer group. The ordinary redeemable share price of € 72.23 was determined based on the following assumptions: Grant date Average revenue growth rates (2023-2027) (%) 16.5 % Average EBITDA margin (2023-2027) (%) 31.0 % Terminal growth rate (2023-2027) (%) 1.5 % After-tax discount rate (%) 9.9 % Average capital expenditure investments (in millions of Euros) 85.8 Dividend yield (%) 0.0 % Expected volatility (%) 34.4 % Expected time period (years) (weighted average of the assumed exit event date scenarios) 1.1 Risk free interest rate (%) (weighted average of the assumed exit event date scenarios) 3.2 % If an exit event of the Company, which is defined as an initial public offering or sale, takes place during the vesting period, the entire award is immediately fully vested. As the Company closed its IPO on October 13, 2023, the entire award vested during the reporting period. For the three months ended December 31, 2023, the Company recognized € 3.6 million of share-based compensation expenses in the statement of comprehensive income in the following expense categories: (In thousands of Euros) Three months ended December 31, 2023 Sales and marketing expenses 406 General administrative expenses 3,185 Total 3,591 The Company paid personal income taxes of € 11.4 million in December 2023 for the fully vested MIP program on behalf of employees. The Company will subsequently be reimbursed by the employees.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Dec. 31, 2023
Disclosure of contingent liabilities [abstract]
Commitments and Contingencies	19. COMMITMENTS AND CONTINGENCIES The Company is defending an action brought by a distributor in France as a result of the termination of a business relationship. The plaintiff's claim amounts to € 94.7 million. The Company has recognized a provision for management’s best estimate of probable outflow. On January 25, 2024, the commercial court of Nancy, France, delivered its ruling in favor of the Company. The plaintiff has the possibility to appeal the ruling. The Company has revised its provision according to the developments of the case.

Related Party Disclosures

Related Party Disclosures	3 Months Ended
	Dec. 31, 2023
Disclosure of Related Party Explanatory [Abstract]
Related Party Disclosures	20. RELATED PARTY DISCLOSURES In the course of the Company’s ordinary business activities, the Company enters into related party transactions with its shareholders and key management personnel. Parent and ultimate controlling party The ultimate controlling party of the Company is L Catterton. Transactions with key management personnel Key management compensation Key management personnel for the periods presented consisted of our Chief Executive Officer, Chief Financial Officer, Chief Communications Officer, Chief Legal Officer, Chief Product Officer, Chief Sales Officer, Chief Technical Operations Officer, President Europe, President Americas and the Board of Directors. Key management compensation is comprised of the following: Three months ended December 31, (In thousands of Euros) 2023 2022 Short-term employee benefits 3,937 4,379 Long-term employee benefits — 62 Post-employment benefits 278 189 Share-based compensation expenses 2,952 — Total 7,167 4,631 The Company paid personal income taxes o f € 6.8 milli on in December 2023 for the fully vested MIP program on behalf of key management personnel. As of December 31, 2023, the Company has a receivable of this amount recorded in non-current 'Other Assets', because the key management personnel will subsequently reimburse the Company. Key management personnel transactions The Company maintains a long-term business relationship related to the production of advertising content with a model agency, owned by a family member of our Chief Executive Officer. The Company incurred marketing expenses in the amount of € 0.1 million during the three months ended December 31, 2022. No expenses were recognized for the three months ended December 31, 2023. The Company leased administrative buildings from Ockenfels Group GmbH & Co. KG (“Ockenfels”), an entity managed by our Chief Executive Officer and controlled by the predecessor shareholders, AB-Beteiligungs GmbH and CB Beteiligungs GmbH & Co. KG, and made lease payments (equivalent to the expenses for the period) in the amount of € 0.1 million during the three months ended December 31, 2023 and € 0.1 million during the three months ended December 31, 2022. The lease liability amounted to € 1.8 million and € 2.0 million as of December 31, 2023 and December 31, 2022, respectively. As of September 30, 2023, the Company had outstanding receivables of € 2.5 million against Ockenfels. As of December 31, 2023, there is no longer a material outstanding balance against Ockenfels. Other related party transactions Transactions with other related parties primarily consisted of consulting fees for management services provided by and expenses reimbursed to L Catterton Management Company LLC and related entities controlled by the shareholders of the Company. During the three months ended December 31, 2023 and December 31, 2022, consulting fees and cost reimbursement of € 0.1 million and € 0.1 million, respectively, were recognized as expenses. As of December 31, 2023, the Company has a lease liability of € 0.1 million owed to CB Beteiligungs GmbH & Co. KG . As of September 30, 2023, the corresponding lease liability amounted to € 0.1 mill ion. As described in Note 12, in October 2023 the Company entered into the TRA with the pre-IPO shareholder MidCo. There were no payments made under the TRA during the three months ended December 31, 2023. The outstanding balance of the TRA liability as of December 31, 2023 was € 333.2 mil lion.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
	Dec. 31, 2023
Significant Accounting Policies [Abstract]
Change in accounting estimate	Change in accounting estimateThe Company distributes its footwear produced predominantly in Germany and Portugal to its own (distribution) legal entities around the world with an intercompany margin, which is being eliminated at consolidated level. The intercompany profit elimination ("ICP") has been calculated and applied on a consistent manner up through September 30, 2023. However, it is based on various, high-level assumptions. This ICP model has been replaced with a more detailed method reflecting the precise inventory turnover rate per product style, i.e., Boston, Arizona, and color. This more accurate computation also has a foreign currency impact on the Cost of Sales converted to the reporting currency Euro. If the prior ICP model computation had been applied still in this fiscal year, the Company would have recorded an incremental expense (Cost of Sales) of €13.5 for both aspects (ICP and FX) in the three months ended December 31, 2023.
Deferred offering costs	Deferred offering costs The Company capitalizes certain legal, professional accounting, and other third-party fees that are directly associated with the issuance of shares as deferred offering costs and recorded these in line item other financial assets until such equity financing is consummated. After consummation, these deferred costs are recorded within equity as a reduction to the share premium generated as a result of the offering. The Company closed its initial public offering during the three months ended December 31, 2023, and therefore a total of € 2.9 million deferred offering costs were recorded as a reduction of share premium. No deferred offering costs were capitalized as of December 31, 2023 .
New and amended standards and interpretations adopted by the Company	New and amended standards and interpretations adopted by the Company The following amended standards became effective for the Company’s fiscal year beginning on October 1, 2023, but did not have a material impact on the unaudited interim condensed consolidated financial statements of the Company: • IFRS 17 - Insurance Contracts (effective for annual periods beginning on or after January 1, 2023). • Amendments to IFRS 17 – Insurance Contracts (effective for annual periods beginning on or after January 1, 2023). • IFRS 17 and IFRS 9 – Initial application of IFRS 17 and IFRS 9 – Comparative Information (effective for annual periods beginning on or after January 1, 2023). • Amendments to IAS 8 – Definition of Accounting Estimates (effective for annual periods beginning on or after January 1, 2023). • Amendments to IAS 1 and IFRS Practice Statement 2 - Disclosure of Accounting Policies (effective for annual periods beginning on or after January 1, 2023). • Amendments to IAS 12 – Deferred Tax related to Assets and Liabilities arising from a Single Transaction (effective for annual periods beginning on or after January 1, 2023). • Amendments to IAS 12 – International Tax Reform - Pillar 2 Model Rules (effective for annual periods beginning on or after January 1, 2023, however a temporary exception from accounting for deferred taxes arising from the implementation of the OECD’s Pillar Two model rules is to be applied retroactively). The mandatory temporary exemption to account for deferred taxes has been applied.
New and amended standards and interpretations issued but not yet effective	New and amended standards and interpretations issued but not yet effective The following standard amendments will be effective beginning October 1, 2024 and are not expected to have a material impact on the unaudited interim condensed consolidated financial statements of the Company: • Amendments to IAS 1 – Non-current liabilities with Covenants (effective for annual periods beginning on or after January 1, 2024). • Amendments to IAS 1 – Classification of Liabilities as current or non-current (effective for annual periods beginning on or after January 1, 2024). • Amendments to IFRS 16 – Lease liability in a sale and lease back (effective for annual periods beginning on or after January 1, 2024). • Amendments to IAS 7 and IFRS 7 – Supplier Finance Arrangements (effective for annual periods beginning on or after January 1, 2024). • Amendments to IAS 21 – Lack of Exchangeability (effective for annual periods beginning on or after January 1, 2025). • Amendments to IFRS 10 and IAS 28 – Sale or contribution of assets between an investor and its associate or joint venture (available for optional adoption/ effective date deferred indefinitely).

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	3 Months Ended
	Dec. 31, 2023
Disclosure of fair value measurement [abstract]
Schedule of Fair Values and Fair Value Hierarchy of Financial Instruments Carried at Fair Value on Recurring Basis	The following table presents the fair values and fair value hierarchy of the Company’s financial instruments that are carried at fair value on a recurring basis in the consolidated statements of financial position: Fair value (In thousands of Euros) Level Measurement December 31, September 30, Derivative assets 36,727 31,708 Derivative assets not designated as hedging instruments 2 FVtPL 35,629 28,795 Derivative assets designated as hedging instruments 2 FVtOCI 1,098 2,913 Derivative liabilities 2 FVtPL 480 6,925
Schedule of Fair Value and Fair Value Hierarchy of Loans and Borrowings Carried at Amortized Cost	The following table presents the fair value and fair value hierarchy of the Company’s loans and borrowings carried at amortized cost: (In thousands of Euros) Level Nominal value Carrying value Fair value December 31, 2023 Term Loan (EUR) 2 375,000 369,388 384,315 Term Loan (USD) 2 299,083 296,974 312,364 Vendor Loan 2 199,560 207,437 189,090 Senior Notes 2 428,500 442,393 414,149 September 30, 2023 Term Loan (EUR) 2 375,000 368,701 348,426 Term Loan (USD) 2 781,315 730,855 694,889 Vendor Loan 2 299,560 305,048 235,687 Senior Notes 2 428,500 448,434 373,682

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Dec. 31, 2023
Disclosure of operating segments [abstract]
Schedule of Operating Segments	Assets and liabilities are neither reported nor reviewed by the CODM at the operating segment level. Three months ended December 31, 2023 (In thousands of Euros) Americas Europe APMA Total Reportable Segments Corporate / Other Total Revenue 181,453 80,134 39,478 301,065 1,859 302,924 Adjusted EBITDA 51,553 23,137 12,184 86,874 ( 5,518 ) 81,356 IPO-related costs ( 7,294 ) Realized and unrealized FX gains / losses ( 11,655 ) Share-based compensation expenses ( 3,591 ) EBITDA 58,817 Depreciation and amortization ( 23,247 ) Finance cost, net ( 36,050 ) Profit before tax ( 480 ) Three months ended December 31, 2022 (In thousands of Euros) Americas Europe APMA Total Reportable Segments Corporate / Other Total Revenue 159,799 60,517 26,913 247,229 1,261 248,490 Adjusted EBITDA 54,632 13,492 6,088 74,212 ( 1,817 ) 72,395 IPO-related costs ( 5,343 ) Realized and unrealized FX gains / losses ( 30,830 ) Other ( 1,569 ) EBITDA 34,654 Depreciation and amortization ( 20,417 ) Finance cost, net ( 25,098 ) Profit before tax ( 10,861 )

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Dec. 31, 2023
Disclosure Of Inventories [Abstract]
Summary of Inventories	(In thousands of Euros) December 31, September 30, Raw materials 81,567 69,580 Work in progress 29,166 23,102 Finished goods 533,634 502,410 Total inventories at the lower of cost and net realizable value 644,367 595,092

Financial Instruments and Fin_2

Financial Instruments and Financial Risk Management (Tables)	3 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about financial instruments [abstract]
Schedule of Fair Values and Fair Value Hierarchy of Financial Instruments Carried at Fair Value on Recurring Basis	The following table presents the fair values and fair value hierarchy of the Company’s financial instruments that are carried at fair value on a recurring basis in the consolidated statements of financial position: Fair value (In thousands of Euros) Level Measurement December 31, September 30, Derivative assets 36,727 31,708 Derivative assets not designated as hedging instruments 2 FVtPL 35,629 28,795 Derivative assets designated as hedging instruments 2 FVtOCI 1,098 2,913 Derivative liabilities 2 FVtPL 480 6,925
Schedule of Fair Value and Fair Value Hierarchy of Loans and Borrowings Carried at Amortized Cost	The following table presents the fair value and fair value hierarchy of the Company’s loans and borrowings carried at amortized cost: (In thousands of Euros) Level Nominal value Carrying value Fair value December 31, 2023 Term Loan (EUR) 2 375,000 369,388 384,315 Term Loan (USD) 2 299,083 296,974 312,364 Vendor Loan 2 199,560 207,437 189,090 Senior Notes 2 428,500 442,393 414,149 September 30, 2023 Term Loan (EUR) 2 375,000 368,701 348,426 Term Loan (USD) 2 781,315 730,855 694,889 Vendor Loan 2 299,560 305,048 235,687 Senior Notes 2 428,500 448,434 373,682

Loans and Borrowings (Tables)

Loans and Borrowings (Tables)	3 Months Ended
	Dec. 31, 2023
Disclosure of detailed information about borrowings [abstract]
Schedule of Principal and Interest Payable Amounts Outstanding	The Company has the following principal and interest payable amounts outstanding for loans and borrowings: (In thousands of Euros) Currency Year of maturity December 31, September 30, Non-current liabilities Term Loan (EUR) EUR 2028 375,000 375,000 Term Loan (USD) USD 2028 296,103 730,159 Vendor Loan EUR 2029 199,560 299,560 Senior Notes EUR 2029 428,500 428,500 1,299,163 1,833,220 Senior Note embedded derivative 28,638 28,638 Less: amortization under the effective interest method ( 35,016 ) ( 46,163 ) 1,292,785 1,815,695 Current liabilities Term Loan (EUR) interest payable EUR N/A 4,358 4,197 Term Loan (USD) - current portion USD 2028 2,980 7,347 Term Loan (USD) interest payable USD N/A 4,444 10,938 Vendor Loan interest payable EUR N/A 7,877 5,487 Senior Notes interest payable EUR N/A 3,749 9,373 23,408 37,343

Deferred Income (Tables)

Deferred Income (Tables)	3 Months Ended
	Dec. 31, 2023
Deferred income [abstract]
Summary of Deferred Income	(In thousands of Euros) Government Grants Other Balance at September 30, 2023 10,634 2,680 Pledged during the year 84 — Received during the year — 140 Released to the statement of comprehensive income ( 125 ) — Impact of foreign currency translation — ( 114 ) Balance at December 31, 2023 10,593 2,706 current — — non-current 10,593 2,706

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	3 Months Ended
	Dec. 31, 2023
Revenue [abstract]
Summary of Disaggregation of Revenue by Sales Channels	For disaggregation of revenue by geography refer to Note 5 – Segment information . Disaggregation of revenue by sales channels was as follows: Three months ended December 31, (In thousands of Euros) 2023 2022 B2B 140,410 117,794 DTC 160,655 129,435 Other 1,859 1,261 Total revenue 302,924 248,490

Operating Expenses (Tables)

Operating Expenses (Tables)	3 Months Ended
	Dec. 31, 2023
Notes and other explanatory information [abstract]
Summary of Cost of Sales	Cost of sales Three months ended December 31, (In thousands of Euros) 2023 2022 Depreciation & amortization ( 4,397 ) ( 3,413 ) Personnel costs ( 40,388 ) ( 33,461 ) Cost of materials ( 54,877 ) ( 41,568 ) Properties & buildings maintenance, occupancy and incidental costs ( 6,613 ) ( 4,270 ) Logistic expenses ( 1,289 ) ( 1,007 ) IT & Consulting ( 8,221 ) ( 6,401 ) Other ( 2,271 ) ( 5,052 ) Cost of sales ( 118,056 ) ( 95,170 )
Summary of Selling and Distribution Expenses	Selling and distribution expenses Three months ended December 31, (In thousands of Euros) 2023 2022 Depreciation & amortization ( 14,681 ) ( 14,305 ) Personnel costs ( 21,105 ) ( 18,019 ) Marketing and selling expenses ( 29,042 ) ( 23,572 ) Logistic expenses ( 29,764 ) ( 13,358 ) IT & Consulting ( 8,204 ) ( 12,429 ) Other ( 687 ) ( 4,436 ) Selling and distribution expenses ( 103,484 ) ( 86,119 )
Summary of General Administration Expenses	General administration expenses Three months ended December 31, (In thousands of Euros) 2023 2022 Depreciation & amortization ( 4,169 ) ( 2,699 ) Personnel costs ( 16,837 ) ( 12,466 ) Insurance ( 1,538 ) ( 627 ) IT & Consulting ( 73 ) ( 4,535 ) Other ( 11,773 ) ( 1,805 ) General administration expenses ( 34,391 ) ( 22,133 )

Income Tax (Tables)

Income Tax (Tables)	3 Months Ended
	Dec. 31, 2023
Disclosure of income tax [abstract]
Schedule of Major Components of Income Tax Expense	The major components of income tax expenses are as follows: Three months ended December 31, (In thousands of Euros) 2023 2022 Current income taxes ( 4,610 ) ( 4,648 ) Deferred income taxes ( 2,064 ) 6,322 Income tax expense ( 6,674 ) 1,674

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Dec. 31, 2023
Earnings per share [abstract]
Schedule of Calculation of Earnings Per Share	The calculation of earnings per share is as follows: Three months ended December 31, (In thousands of Euros, except share and per share information) 2023 2022 Weighted number of outstanding shares 186,920,154 182,721,369 Number of shares with dilutive effects — — Weighted number of outstanding shares (diluted and undiluted) 186,920,154 182,721,369 Net profit (loss) attributable to ordinary shareholders ( 7,154 ) ( 9,187 ) Basic ( 0.04 ) ( 0.05 ) Diluted ( 0.04 ) ( 0.05 )

Share-based Compensation (Table

Share-based Compensation (Tables)	3 Months Ended
	Dec. 31, 2023
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Summary of Fair Value At Grant Date Estimate Using Discounted Cash Flow Model and Black-Scholes Option Pricing Model	The fair value at grant date was estimated using a Discounted Cash Flow model and then a Black-Scholes option pricing model, weighted for the assigned probability of each exit event date scenario. The model takes into account, among other things, a self-investment as well as the potential development of Birkenstock's ordinary redeemable share price. The historical volatility was derived from a peer group. The ordinary redeemable share price of € 72.23 was determined based on the following assumptions: Grant date Average revenue growth rates (2023-2027) (%) 16.5 % Average EBITDA margin (2023-2027) (%) 31.0 % Terminal growth rate (2023-2027) (%) 1.5 % After-tax discount rate (%) 9.9 % Average capital expenditure investments (in millions of Euros) 85.8 Dividend yield (%) 0.0 % Expected volatility (%) 34.4 % Expected time period (years) (weighted average of the assumed exit event date scenarios) 1.1 Risk free interest rate (%) (weighted average of the assumed exit event date scenarios) 3.2 %
Summary of Stock-Based Compensation Expenses Recognized	For the three months ended December 31, 2023, the Company recognized € 3.6 million of share-based compensation expenses in the statement of comprehensive income in the following expense categories: (In thousands of Euros) Three months ended December 31, 2023 Sales and marketing expenses 406 General administrative expenses 3,185 Total 3,591 The Company paid personal income taxes of € 11.4 million in December 2023 for the fully vested MIP program on behalf of employees. The Company will subsequently be reimbursed by the employees.

Related Party Disclosures (Tabl

Related Party Disclosures (Tables)	3 Months Ended
	Dec. 31, 2023
Disclosure of transactions between related parties [line items]
Related Party Transactions	Key management compensation is comprised of the following: Three months ended December 31, (In thousands of Euros) 2023 2022 Short-term employee benefits 3,937 4,379 Long-term employee benefits — 62 Post-employment benefits 278 189 Share-based compensation expenses 2,952 — Total 7,167 4,631 The Company paid personal income taxes o f € 6.8 milli on in December 2023 for the fully vested MIP program on behalf of key management personnel. As of December 31, 2023, the Company has a receivable of this amount recorded in non-current 'Other Assets', because the key management personnel will subsequently reimburse the Company.

Significant Accounting Polici_3

Significant Accounting Policies - Additional Information (Details)	3 Months Ended
	Dec. 31, 2023 EUR (€)
Disclosure of changes in accounting estimates [line items]
Cost of Sales	€ 13,500,000
Deferred offering costs	2,900,000
Deferred offering costs capitalized	€ 0

Segment Information - Additiona

Segment Information - Additional Information (Details)	3 Months Ended
	Dec. 31, 2023 Hub Segment
Disclosure of operating segments [abstract]
Number of geographical hubs | Hub	4
Number of reportable segments | Segment	3

Segment Information - Schedule

Segment Information - Schedule of Operating Segments (Details) - EUR (€) € in Thousands	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of operating segments [line items]
Revenue	€ 302,924	€ 248,490
Adjusted EBITDA	81,356	72,395
IPO-related costs	(7,294)	(5,343)
Realized and unrealized FX gains / losses	(11,655)	(30,830)
Share-based compensation expenses	(3,591)
Other		(1,569)
EBITDA	58,817	34,654
Depreciation and amortization	(23,247)	(20,417)
Finance costs, net	(36,050)	(25,098)
Profit (loss) before tax	(480)	(10,861)
Total Reportable Segments
Disclosure of operating segments [line items]
Revenue	301,065	247,229
Adjusted EBITDA	86,874	74,212
Total Reportable Segments | Americas
Disclosure of operating segments [line items]
Revenue	181,453	159,799
Adjusted EBITDA	51,553	54,632
Total Reportable Segments | Europe
Disclosure of operating segments [line items]
Revenue	80,134	60,517
Adjusted EBITDA	23,137	13,492
Total Reportable Segments | APMA
Disclosure of operating segments [line items]
Revenue	39,478	26,913
Adjusted EBITDA	12,184	6,088
Corporate / Other
Disclosure of operating segments [line items]
Revenue	1,859	1,261
Adjusted EBITDA	€ (5,518)	€ (1,817)

Property, Plant and Equipment A

Property, Plant and Equipment Additional Information (Details) - EUR (€) € in Millions	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about property, plant and equipment [abstract]
Property, plant and equipment acquired	€ 16.4	€ 25.7

Right-of-Use assets - Additiona

Right-of-Use assets - Additional Information (Details) - EUR (€) € in Thousands	Dec. 31, 2023	Sep. 30, 2023
Presentation of leases for lessee [abstract]
Right-of-use assets	€ 148,245	€ 122,984

Business Combinations - Additio

Business Combinations - Additional Information (Details) - EUR (€) € in Thousands	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of detailed information about business combination [line items]
Earnings before interest, taxes, depreciation and amortization	€ 184,868	€ 153,320

Goodwill - Summary of Goodwill

Goodwill - Summary of Goodwill (Details) € in Thousands	Dec. 31, 2023 EUR (€)
Disclosure of reconciliation of changes in goodwill [line items]
Goodwill at beginning of period	€ 1,593,917
Goodwill at end of period	€ 1,564,791

Goodwill - Summary of Goodwil_2

Goodwill - Summary of Goodwill Balance Allocation into Applicable Groups of CGUs (Details) - EUR (€) € in Thousands	Dec. 31, 2023	Sep. 30, 2023
Disclosure of reconciliation of changes in goodwill [line items]
Goodwill	€ 1,564,791	€ 1,593,917

Intangible Assets - Summary of

Intangible Assets - Summary of Intangible Assets (Details) € in Thousands	Dec. 31, 2023 EUR (€)
Disclosure of detailed information about intangible assets [line items]
Beginning balance	€ 1,705,736
Ending balance	€ 1,661,224

Inventories - Summary of Invent

Inventories - Summary of Inventories (Details) - EUR (€) € in Thousands	Dec. 31, 2023	Sep. 30, 2023
Classes of current inventories [abstract]
Raw materials	€ 81,567	€ 69,580
Work in progress	29,166	23,102
Finished goods	533,634	502,410
Total inventories at the lower of cost and net realizable value	€ 644,367	€ 595,092

Inventories - Additional Inform

Inventories - Additional Information (Details) - EUR (€)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Inventories [Abstract]
Inventories expenses recognised as during period	€ 54,900,000	€ 41,600,000
Inventory write-down	€ 2,700,000	€ 0

Equity - Additional Information

Equity - Additional Information (Details) € / shares in Units, $ / shares in Units, € in Millions, $ in Millions					3 Months Ended
	Oct. 13, 2023 EUR (€) shares	Oct. 13, 2023 USD ($) $ / shares shares	Oct. 10, 2023 shares	Oct. 02, 2023 € / shares shares	Dec. 31, 2023 EUR (€) shares	Sep. 30, 2023 shares	Dec. 31, 2022 shares	Sep. 30, 2022 shares
Disclosure Of Detailed Information About Equity [line items]
Underwriting commission fees					€ 19.8
Deferred offering costs					€ 2.9
Ordinary Shares
Disclosure Of Detailed Information About Equity [line items]
Number of ordinary shares | shares				182,721,369	187,825,592	182,721,369	182,721,369	182,721,369
Ordinary Shares
Disclosure Of Detailed Information About Equity [line items]
Number of ordinary shares issued | shares	10,752,688	10,752,688
Initial public offering price | $ / shares		$ 46
Total proceeds from IPO | $		$ 473.6
Early repayment of borrowings	€ 100				€ 100
Description of no par value ordinary shares				Prior to the IPO, the Company performed a capital reorganization. On October 2, 2023, the Company converted its share capital, comprised of 182,721,369 ordinary shares of €1.00 each into 182,721,369 no par value ordinary shares.
Par value per share | € / shares				€ 1
Shares repurchased of ordinary shares | shares			5,648,465
Initial Public Offering
Disclosure Of Detailed Information About Equity [line items]
Underwriting commission fees	19.8
Deferred offering costs	€ 2.9
USD Term Loan | Ordinary Shares
Disclosure Of Detailed Information About Equity [line items]
Early repayment of borrowings | $		$ 450

Financial Instruments and Fin_3

Financial Instruments and Financial Risk Management - Schedule of Fair Values and Fair Value Hierarchy of Financial Instruments Carried at Fair Value on Recurring Basis (Details) - Recurring Fair Value Measurement - EUR (€) € in Thousands	Dec. 31, 2023	Sep. 30, 2023
Disclosure of detailed information about financial instruments [line items]
Derivative assets	€ 36,727	€ 31,708
Level 2 | FVtPL
Disclosure of detailed information about financial instruments [line items]
Derivative liabilities	480	6,925
Level 2 | FVtPL
Disclosure of detailed information about financial instruments [line items]
Derivative assets not designated as hedging instruments	35,629	28,795
Level 2 | FVtOCI
Disclosure of detailed information about financial instruments [line items]
Derivative assets designated as hedging instruments	€ 1,098	€ 2,913

Financial Instruments and Fin_4

Financial Instruments and Financial Risk Management - Schedule of Fair Value and Fair Value Hierarchy of Loans and Borrowings Carried at Amortized Cost (Details) - Level 2 - EUR (€) € in Thousands	Dec. 31, 2023	Sep. 30, 2023
Vendor Loan
Disclosure of fair value measurement of liabilities [line items]
Nominal value	€ 199,560	€ 299,560
Senior Notes
Disclosure of fair value measurement of liabilities [line items]
Nominal value	428,500	428,500
EUR | Term Loan
Disclosure of fair value measurement of liabilities [line items]
Nominal value	375,000	375,000
USD | Term Loan
Disclosure of fair value measurement of liabilities [line items]
Nominal value	299,083	781,315
Fair Value | Vendor Loan
Disclosure of fair value measurement of liabilities [line items]
Loans and borrowings	189,090	235,687
Fair Value | Senior Notes
Disclosure of fair value measurement of liabilities [line items]
Loans and borrowings	414,149	373,682
Fair Value | EUR | Term Loan
Disclosure of fair value measurement of liabilities [line items]
Loans and borrowings	384,315	348,426
Fair Value | USD | Term Loan
Disclosure of fair value measurement of liabilities [line items]
Loans and borrowings	312,364	694,889
Carrying Value | Vendor Loan
Disclosure of fair value measurement of liabilities [line items]
Loans and borrowings	207,437	305,048
Carrying Value | Senior Notes
Disclosure of fair value measurement of liabilities [line items]
Loans and borrowings	442,393	448,434
Carrying Value | EUR | Term Loan
Disclosure of fair value measurement of liabilities [line items]
Loans and borrowings	369,388	368,701
Carrying Value | USD | Term Loan
Disclosure of fair value measurement of liabilities [line items]
Loans and borrowings	€ 296,974	€ 730,855

Financial Instruments and Fin_5

Financial Instruments and Financial Risk Management - Additional Information (Details) - EUR (€)	3 Months Ended	12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023
Disclosure of fair value measurement [abstract]
Transfers out of level 1 into level 2 of fair value hierarchy, liabilities held at end of reporting period	€ 0	€ 0
Transfers out of level 2 into level 1 of fair value hierarchy, liabilities held at end of reporting period	€ 0	€ 0

Trade and Other Receivables - S

Trade and Other Receivables - Schedule of Trade and Other Receivables (Details) - EUR (€) € in Thousands	Dec. 31, 2023	Sep. 30, 2023
Trade and other receivables [abstract]
Trade and other receivables, current	€ 79,497	€ 91,764

Other Assets - Other Assets Non

Other Assets - Other Assets Non-Current and Current (Details) - EUR (€) € in Thousands	Dec. 31, 2023	Sep. 30, 2023
Subclassifications of assets, liabilities and equities [abstract]
Other non-current assets	€ 52,045	€ 38,234
Other current assets	€ 36,849	€ 37,789

Cash and Cash Equivalents - Sum

Cash and Cash Equivalents - Summary of Cash and Cash Equivalents (Details) - EUR (€) € in Thousands	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022
Cash and cash equivalent [line items]
Cash and cash equivalents	€ 169,379	€ 344,408	€ 171,060	€ 307,078

Loans and Borrowings - Schedule

Loans and Borrowings - Schedule of Principal and Interest Payable Outstanding Amounts (Details) - EUR (€) € in Thousands	3 Months Ended
	Dec. 31, 2023	Sep. 30, 2023
Disclosure of detailed information about borrowings [line items]
Non-current liabilities, gross	€ 1,299,163	€ 1,833,220
Senior Note embedded derivative	28,638	28,638
Less: amortization under the effective interest method	(35,016)	(46,163)
Non-current liabilities	1,292,785	1,815,695
Current liabilities	€ 23,408	37,343
Term Loan | EUR
Disclosure of detailed information about borrowings [line items]
Borrowings, maturity	2028
Non-current liabilities, gross	€ 375,000	375,000
Term Loan | USD
Disclosure of detailed information about borrowings [line items]
Borrowings, maturity	2028
Non-current liabilities, gross	€ 296,103	730,159
Current liabilities	€ 2,980	7,347
Vendor Loan | EUR
Disclosure of detailed information about borrowings [line items]
Borrowings, maturity	2029
Non-current liabilities, gross	€ 199,560	299,560
Senior Notes | EUR
Disclosure of detailed information about borrowings [line items]
Borrowings, maturity	2029
Non-current liabilities, gross	€ 428,500	428,500
Term Loan interest payable
Disclosure of detailed information about borrowings [line items]
Current liabilities	23,408	37,343
Term Loan interest payable | EUR
Disclosure of detailed information about borrowings [line items]
Current liabilities	4,358	4,197
Term Loan interest payable | USD
Disclosure of detailed information about borrowings [line items]
Current liabilities	4,444	10,938
Vendor Loan interest payable | EUR
Disclosure of detailed information about borrowings [line items]
Current liabilities	7,877	5,487
Senior Notes interest payable | EUR
Disclosure of detailed information about borrowings [line items]
Current liabilities	€ 3,749	€ 9,373

Loans and Borrowings - Reconcil

Loans and Borrowings - Reconciliation of Financial Liabilities (Details) - EUR (€) € in Thousands	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Changes from financing cash flows
Repayments of loans and borrowings	€ (524,514)	€ (1,995)
Interest paid	€ (34,423)	€ (38,972)

Loans and Borrowings - Addition

Loans and Borrowings - Additional Information (Details) € in Millions, $ in Millions			3 Months Ended
	Oct. 13, 2023 EUR (€)	Oct. 13, 2023 USD ($)	Dec. 31, 2023 EUR (€)	Dec. 31, 2023 USD ($)
Ordinary Shares
Disclosure of detailed information about borrowings [line items]
Early repayment of borrowings | €	€ 100		€ 100
USD Term Loan
Disclosure of detailed information about borrowings [line items]
Redemption payment				$ 450
USD Term Loan | Ordinary Shares
Disclosure of detailed information about borrowings [line items]
Early repayment of borrowings		$ 450

Tax Receivable Agreement (Addit

Tax Receivable Agreement (Additional Information) (Details) € in Millions, $ in Millions	Oct. 10, 2023 USD ($) shares	Dec. 31, 2023 EUR (€)	Oct. 10, 2023 EUR (€)
Tax Receivable Agreement [Line Items]
Payments to the tax receivable agreement (tra)	85%
Benefit of the remaining applicable tax savings	15%
Terms of certain tax benefits related to TRA payments	13 years
Future payments expected to be made under Tax Receivable Agreement | $	$ 554.7
Future expected period of payment to be made under tax receivable agreement	13 years
TRA liability | €		€ 333.2	€ 343.6
Ordinary Shares
Tax Receivable Agreement [Line Items]
Shares repurchased of ordinary shares | shares	5,648,465

Income Tax - Schedule of Major

Income Tax - Schedule of Major Components of Income Tax Expense (Details) - EUR (€) € in Thousands	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of income tax [abstract]
Current income taxes	€ (4,610)	€ (4,648)
Deferred income taxes	(2,064)	6,322
Income tax expense	€ (6,674)	€ 1,674

Income Tax - Additional Informa

Income Tax - Additional Information (Details)	12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Income Tax [Line items]
Estimated income tax rate		34.60%
Scenario Forecast
Income Tax [Line items]
Estimated income tax rate	34.40%

Other Financial Liabilities - S

Other Financial Liabilities - Summary of Other Financial Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2023	Sep. 30, 2023
Categories of current financial liabilities [abstract]
Other current financial liabilities	€ 913	€ 7,085

Other Provions - Summary of Oth

Other Provions - Summary of Other Provisions (Details) - EUR (€) € in Thousands	Dec. 31, 2023	Sep. 30, 2023
Disclosure of other provisions [line items]
Total Current provisions	€ 24,574	€ 36,495
Total Non-Current provisions	€ 1,807	€ 2,074

Deferred Income - Summary of De

Deferred Income - Summary of Deferred Income (Details) - EUR (€) € in Thousands	3 Months Ended
	Dec. 31, 2023	Sep. 30, 2023
Disclosure of deferred income [line items]
Current	€ 0	€ 2,680
Non-current	13,299	€ 10,634
Government
Disclosure of deferred income [line items]
Beginning balance	10,634
Pledged during the year	84
Released to the statement of comprehensive income	(125)
Ending balance	10,593
Non-current	10,593
Other
Disclosure of deferred income [line items]
Beginning balance	2,680
Received during the year	140
Impact of foreign currency translation	(114)
Ending balance	2,706
Non-current	€ 2,706

Deferred Income - Additional In

Deferred Income - Additional Information (Details) € in Millions	3 Months Ended
	Dec. 31, 2023 Job	Nov. 23, 2023 EUR (€)	Sep. 30, 2023 EUR (€)
Disclosure of non-adjusting events after reporting period [line items]
Government grant			€ 11.3
Number of permanent jobs | Job	400
Cash from State of Mecklenburg-Vorpommern
Disclosure of non-adjusting events after reporting period [line items]
Other receivable financial assets		€ 8.7

Other Current Liabilities - Sum

Other Current Liabilities - Summary of Other Current Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2023	Sep. 30, 2023
Other Current Liabilities [abstract]
Other current liabilities, Total	€ 12,021	€ 15,961

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Summary of Disaggregation of Revenue by Sales Channels (Details) - EUR (€) € in Thousands	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total revenue	€ 302,924	€ 248,490
B2B
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total revenue	140,410	117,794
DTC
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total revenue	160,655	129,435
Other
Disclosure of disaggregation of revenue from contracts with customers [line items]
Total revenue	€ 1,859	€ 1,261

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Schedule of Movements of Contract Liabilities (Details) € in Thousands	Dec. 31, 2023 EUR (€)
Contract liabilities [abstract]
At the beginning of the period/year	€ 7,018
At the end of the period/year	€ 14,995

Operating Expenses - Summary of

Operating Expenses - Summary of Cost of Sales (Details) - EUR (€) € in Thousands	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of attribution of expenses by nature to their function [line items]
Depreciation and amortization	€ (23,247)	€ (20,417)
Cost of sales	(118,056)	(95,170)
Cost of Sales
Disclosure of attribution of expenses by nature to their function [line items]
Depreciation and amortization	(4,397)	(3,413)
Personnel costs	(40,388)	(33,461)
Cost of materials	(54,877)	(41,568)
Properties & buildings maintenance, occupancy and incidental costs	(6,613)	(4,270)
Logistic expenses	(1,289)	(1,007)
IT & Consulting	(8,221)	(6,401)
Other	€ (2,271)	€ (5,052)

Operating Expenses - Summary _2

Operating Expenses - Summary of Selling and Distribution Expenses (Details) - EUR (€) € in Thousands	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of attribution of expenses by nature to their function [line items]
Depreciation and amortization	€ (23,247)	€ (20,417)
Selling and distribution expenses	(103,484)	(86,119)
Selling and Distribution Expenses
Disclosure of attribution of expenses by nature to their function [line items]
Depreciation and amortization	(14,681)	(14,305)
Personnel costs	(21,105)	(18,019)
Marketing and selling expenses	(29,042)	(23,572)
Logistic expenses	(29,764)	(13,358)
IT & Consulting	(8,204)	(12,429)
Other	€ (687)	€ (4,436)

Operating Expenses - Summary _3

Operating Expenses - Summary of General Administration Expenses (Details) - EUR (€) € in Thousands	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of attribution of expenses by nature to their function [line items]
Depreciation and amortization	€ (23,247)	€ (20,417)
Other	231
General administration expenses	(34,391)	(22,133)
General Administration Expenses
Disclosure of attribution of expenses by nature to their function [line items]
Depreciation and amortization	(4,169)	(2,699)
Personnel costs	(16,837)	(12,466)
Insurance	(1,538)	(627)
IT & Consulting	(73)	(4,535)
Other	€ (11,773)	€ (1,805)

Operating Expenses - Additional

Operating Expenses - Additional Information (Details) € in Thousands	3 Months Ended
	Dec. 31, 2023 EUR (€)
Senior Leadership Team
Disclosure of attribution of expenses by nature to their function [line items]
Deferred compensation plan contribution amount	€ 2,952

Foreign Exchange Gain (Loss) -

Foreign Exchange Gain (Loss) - Summary of Foreign Exchange Gain (Loss) (Details) - EUR (€) € in Thousands	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Foreign exchange gain (loss) [abstract]
Foreign exchange gain (loss)	€ (11,655)	€ (30,830)

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Calculation of Earnings Per Share (Details) - EUR (€) € / shares in Units, € in Thousands	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Earnings per share [abstract]
Weighted number of outstanding shares	186,920,154	182,721,369
Weighted number of outstanding shares (diluted and undiluted)	186,920,154	182,721,369
Net profit (loss) attributable to ordinary shareholders	€ (7,154)	€ (9,187)
Basic	€ (0.04)	€ (0.05)
Diluted	€ (0.04)	€ (0.05)

Share-based Compensation - Addi

Share-based Compensation - Additional Information (Details) € / shares in Units, € in Thousands	1 Months Ended	3 Months Ended
	Mar. 31, 2023 shares Tranche € / shares	Dec. 31, 2023 EUR (€)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Recognized share-based compensation expense | €		€ 3,591
Management Investment Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Personal income taxes paid for the fully vested program | €		€ 11,400
Management Investment Plan | BK LC Manco GmbH & Co. KG
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of shares granted | shares	1,197,100
Number of tranches | Tranche	5
Percentage of shares granted to each tranche	20%
Number of shares forfeited/ canceled/ settled | shares	0
Granted shares vesting period	4 years
Percentage of shares granted vesting after each year of service	20%
Percentage of shares granted that vests with occurrence of an exit	20%
Minimum required period for exit event to occur after the grant	12 months
Weighted average fair value of the awards granted | € / shares	€ 57.57
Ordinary redeemable share price | € / shares	€ 72.23
Management Investment Plan | BK LC Manco GmbH & Co. KG | First Tranche
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of grants included in grant date fair value, accounted after occurrence of exit event	20%

Share-based Compensation - Summ

Share-based Compensation - Summary of Fair Value At Grant Date Estimate Using Discounted Cash Flow Model and Black-Scholes Option Pricing Model (Details) € in Millions	Mar. 10, 2023 EUR (€)
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Average revenue growth rates (2023-2027) (%)	16.50%
Average EBITDA margin (2023-2027) (%)	31%
Terminal growth rate (2023-2027) (%)	1.50%
After-tax discount rate (%)	9.90%
Average capital expenditure investments	€ 85.8
Dividend yield (%)	0%
Expected volatility (%)	34.40%
Expected time period (years) (weighted average of the assumed exit event date scenarios)	1 year 1 month 6 days
Risk free interest rate (%) (weighted average of the assumed exit event date scenarios)	3.20%

Share-based Compensation - Su_2

Share-based Compensation - Summary of Stock-Based Compensation Expenses Recognized (Details) € in Thousands	3 Months Ended
	Dec. 31, 2023 EUR (€)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Recognized share-based compensation expense	€ 3,591
Sales and Marketing Expenses
Disclosure of terms and conditions of share-based payment arrangement [line items]
Recognized share-based compensation expense	406
General Administrative Expenses
Disclosure of terms and conditions of share-based payment arrangement [line items]
Recognized share-based compensation expense	€ 3,185

Commitments And Contingencies -

Commitments And Contingencies - Additional Information (Details) € in Millions	3 Months Ended
	Dec. 31, 2023 EUR (€)
Disclosure of contingent liabilities [abstract]
Plaintiff claim amount	€ 94.7

Related Party Disclosures - Rel

Related Party Disclosures - Related Party Transactions (Details) - Key Management Personnel - EUR (€) € in Thousands	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of transactions between related parties [line items]
Short-term employee benefits	€ 3,937	€ 4,379
Long-term employee benefits		62
Post-employment benefits	278	189
Share-based compensation expenses	2,952
Key management personnel compensation, Total	€ 7,167	€ 4,631

Related Party Disclosures - Add

Related Party Disclosures - Additional Information (Details) - EUR (€)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Oct. 10, 2023	Sep. 30, 2023
Disclosure of transactions between related parties [line items]
TRA liability	€ 333,200,000		€ 343,600,000
Paid personal income taxes for the fully vested program	11,426,000
Ockenfels
Disclosure of transactions between related parties [line items]
Lease payments	100,000	€ 100,000
Lease liability	1,800,000	2,000,000
Outstanding receivables				€ 2,500,000
Management Investment Plan
Disclosure of transactions between related parties [line items]
Paid personal income taxes for the fully vested program	6,800,000
Other related parties [member]
Disclosure of transactions between related parties [line items]
Marketing expenses	0	100,000
Lease liability	100,000
Consulting fees and cost reimbursements	100,000	€ 100,000
Corresponding lease liability to lease payments	100,000
TRA liability	€ 333,200,000